Changes in extent of ulcerative colitis. A study on the course and prognostic factors

Langholz, Ebbe; Munkholm, Pia; Davidsen, Michael; Nielsen, Ole Haagen; Binder, Vibeke

doi:10.1097/00042737-199604000-00026

Cited by 26 publications

(41 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…UC is characterized by unpredictable bouts of active disease and remission. Within a given cohort of UC patients, approximately one-half are in clinical remission at any one time (2). Acute inflammatory episodes compromise mucosal integrity and are characterized by the mucosal infiltration of mast cells, lymphocytes, macrophages, and activated neutrophils (1).…”

mentioning

confidence: 99%

A pro-resolution mediator, prostaglandin D ₂ , is specifically up-regulated in individuals in long-term remission from ulcerative colitis

Vong

Ferraz

Panaccione

et al. 2010

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Patients with ulcerative colitis (UC) experience unpredictable bouts of active inflammation and ulceration. Relatively little attention has been paid to the role of antiinflammatory mediators in the pathogenesis of UC, although rodent studies suggest an important role of prostaglandin (PG) D 2 in the resolution of tissue injury and inflammation. The present study was performed to determine if colonic PGD 2 synthesis was altered in patients in remission from UC and if expression of the key enzymes and receptors related to PGD 2 was altered. During routine colon-cancer screening, colonic biopsies were obtained from healthy individuals, some of whom had been in remission from UC, without treatment, for >4 y. UC patients with active disease or in medically induced remission were also biopsied. Only patients with active UC exhibited elevated expression of several proinflammatory cytokines (TNFα and IFNγ) and colonic PGE 2 synthesis. In contrast, colonic PGD 2 synthesis was only elevated (∼3-fold) in the healthy individuals with a prior history of UC. This group also exhibited significantly elevated expression of DP1, the key receptor mediating the antiinflammatory actions of PGD 2 . Expression of the synthetic enzymes cyclooxygenase-1, cyclooxygenase-2, and hematopoietic PGD synthase was not altered in the healthy individuals with a prior history of UC. These results show a marked up-regulation of synthesis of an antiinflammatory prostanoid and expression of its receptor, specifically in individuals in long-term remission from UC. This is consistent with animal studies showing the importance of PGD 2 in the induction and maintenance of remission from colitis.inflammation | inflammatory bowel disease | eicosanoid | colon cancer

show abstract

mentioning

confidence: 99%

A pro-resolution mediator, prostaglandin D ₂ , is specifically up-regulated in individuals in long-term remission from ulcerative colitis

Vong

Ferraz

Panaccione

et al. 2010

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

show abstract

“…At diagnosis, UC patients presented with the following disease extent: proctitis [199 patients (21.7%)], left-sided colitis [338 patients (36.8%)] and extensive colitis/pancolitis [381 (41.5%)]. During a median disease duration of 9 [4][5][6][7][8][9][10][11][12][13][14][15][16] years, progression and regression was documented in 145 patients (15.8%) and 149 patients (16.2%) respectively. In addition, 624 patients (68.0%) had a stable disease extent.…”

Section: Resultsmentioning

confidence: 99%

“…Studying an inception cohort of 1161 UC patients from Denmark, Langholz et al found that the probability for further progression of proctosigmoiditis, as assessed by sigmoidoscopy and radiology, was 53% after 25 years. 9 Solberg et al followed an inception cohort of 519 UC patients over the course of 10 years. 15 During the 10-year observation period, 24% (69/288) of patients with proctitis or left-sided colitis had progressed to extensive colitis (a cumulative colectomy rate of 9.8% was also observed).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Systematic analysis of factors associated with progression and regression of ulcerative colitis in 918 patients

Safroneeva

Vavricka

Fournier

et al. 2015

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Patients who initially present with inflammatory disease may eventually develop complications involving strictures or perforation [7]. The extent of UC may also progress over time [8,9]. Traditionally, a step-up approach, with corticosteroids followed by immunosuppressive agents, has been recommended for the management of IBD [10].…”

Section: Introductionmentioning

confidence: 99%

Emerging biologics in inflammatory bowel disease

Chan

2016

J Gastroenterol

View full text Add to dashboard Cite

Early biologic therapy is recommended in patients with inflammatory bowel disease and poor prognostic factors and in those refractory to conventional medications. Anti-tumor necrosis factor (anti-TNF) agents are the most commonly used biologic agents. However, some patients may not have an initial response to anti-TNF therapy, and one-third will develop loss of response over time. Anti-TNF drugs can also be associated with side effects. In addition, the use of biologics is currently limited by their cost, especially in developing countries. A number of new therapeutic targets, including novel small molecules, and cellular therapy are available or under investigation. These novel molecules include oral Janus kinase (JAK) inhibitor (tofacitinib), interleukin inhibitor (ustekinumab), oral SMAD7 antisense oligonucleotide (mongersen), and anti-integrin inhibitors (vedolizumab). Here, we review the mechanisms of action, the efficacy, and the safety data of these novel agents. Biological products that are highly similar to reference biologic products whose patents have expired-also known as ''biosimilars''-can be produced at lower cost with similar efficacy, and are also available for the treatment of IBD. We review the efficacy data for such agents as well.

show abstract

Changes in extent of ulcerative colitis. A study on the course and prognostic factors

Cited by 26 publications

References 0 publications

A pro-resolution mediator, prostaglandin D ₂ , is specifically up-regulated in individuals in long-term remission from ulcerative colitis

A pro-resolution mediator, prostaglandin D ₂ , is specifically up-regulated in individuals in long-term remission from ulcerative colitis

Systematic analysis of factors associated with progression and regression of ulcerative colitis in 918 patients

Emerging biologics in inflammatory bowel disease

Contact Info

Product

Resources

About

Changes in extent of ulcerative colitis. A study on the course and prognostic factors

Cited by 26 publications

References 0 publications

A pro-resolution mediator, prostaglandin D 2 , is specifically up-regulated in individuals in long-term remission from ulcerative colitis

A pro-resolution mediator, prostaglandin D 2 , is specifically up-regulated in individuals in long-term remission from ulcerative colitis

Systematic analysis of factors associated with progression and regression of ulcerative colitis in 918 patients

Emerging biologics in inflammatory bowel disease

Contact Info

Product

Resources

About

A pro-resolution mediator, prostaglandin D ₂ , is specifically up-regulated in individuals in long-term remission from ulcerative colitis

A pro-resolution mediator, prostaglandin D ₂ , is specifically up-regulated in individuals in long-term remission from ulcerative colitis